摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-(-)-3,4,5,10,11,11a-hexahydro-1H-2-thia-4a,10-diazadibenzo[a,d]cycloheptene | 705966-41-2

中文名称
——
中文别名
——
英文名称
(R)-(-)-3,4,5,10,11,11a-hexahydro-1H-2-thia-4a,10-diazadibenzo[a,d]cycloheptene
英文别名
(4aR)-2,4,4a,5,6,11-hexahydro-1H-[1,4]thiazino[3,4-c][1,4]benzodiazepine
(R)-(-)-3,4,5,10,11,11a-hexahydro-1H-2-thia-4a,10-diazadibenzo[a,d]cycloheptene化学式
CAS
705966-41-2
化学式
C12H16N2S
mdl
——
分子量
220.338
InChiKey
JLYHJNDITYMUSR-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    40.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (R)-(-)-3,4,5,10,11,11a-hexahydro-1H-2-thia-4a,10-diazadibenzo[a,d]cycloheptene氯化铵三乙胺 作用下, 以 甲醇二氯甲烷 为溶剂, 生成 N-[4-[(4aR)-1,2,4,4a,5,11-hexahydro-[1,4]thiazino[3,4-c][1,4]benzodiazepine-6-carbonyl]phenyl]-2-phenylbenzamide
    参考文献:
    名称:
    Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates
    摘要:
    Vasopressin receptor antagonists can elicit ion-sparing diuretic effects (i.e., aquaresis) in vivo by blunting the action of the circulating hypophyseal hormone arginine vasopressin. We have identified two new series of basic tricyclic benzodiazepines, represented by general structure 1, which contain compounds that bind with high affinity to human V-2 receptors. For example, (S)-(+)-8 and 5 are potent and selective V2 receptor antagonists with pronounced aquaretic activity in rats on oral administration. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.03.083
  • 作为产物:
    参考文献:
    名称:
    Synthesis, resolution, and absolute configuration of novel tricyclic benzodiazepines
    摘要:
    The synthesis, resolution, and stereochemical characterization of novel piperazino-, thiazino-, and oxazinoberizodiazepines are described. The absolute stereochemistry of the heterotricycles was determined by using X-ray crystallography and the enantiomeric purity was determined by using Pirkle-solvent NMR techniques and chiral HPLC. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetasy.2004.02.028
点击查看最新优质反应信息

文献信息

  • Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates
    作者:Jay M. Matthews、William J. Hoekstra、Alexey B. Dyatkin、Leonard R. Hecker、Dennis J. Hlasta、Brenda L. Poulter、Patricia Andrade-Gordon、Lawrence de Garavilla、Keith T. Demarest、Eric Ericson、Joseph W. Gunnet、William Hageman、Richard Look、John B. Moore、Charles H. Reynolds、Bruce E. Maryanoff
    DOI:10.1016/j.bmcl.2004.03.083
    日期:2004.6
    Vasopressin receptor antagonists can elicit ion-sparing diuretic effects (i.e., aquaresis) in vivo by blunting the action of the circulating hypophyseal hormone arginine vasopressin. We have identified two new series of basic tricyclic benzodiazepines, represented by general structure 1, which contain compounds that bind with high affinity to human V-2 receptors. For example, (S)-(+)-8 and 5 are potent and selective V2 receptor antagonists with pronounced aquaretic activity in rats on oral administration. (C) 2004 Elsevier Ltd. All rights reserved.
  • Synthesis, resolution, and absolute configuration of novel tricyclic benzodiazepines
    作者:Jay M. Matthews、Alexey B. Dyatkin、Mary Evangelisto、Diane A. Gauthier、Leonard R. Hecker、William J. Hoekstra、Fuqiang Liu、Brenda L. Poulter、Kirk L. Sorgi、Bruce E. Maryanoff
    DOI:10.1016/j.tetasy.2004.02.028
    日期:2004.4
    The synthesis, resolution, and stereochemical characterization of novel piperazino-, thiazino-, and oxazinoberizodiazepines are described. The absolute stereochemistry of the heterotricycles was determined by using X-ray crystallography and the enantiomeric purity was determined by using Pirkle-solvent NMR techniques and chiral HPLC. (C) 2004 Elsevier Ltd. All rights reserved.
查看更多